Pliant Therapeutics' (PLRX) shares rose by than 32% in recent Thursday trading after the company said it has begun assembling an external expert panel to evaluate unblinded data from the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis.
This move comes after the trial's independent Data Safety Monitoring Board recommended pausing enrollment and dosing, the company said, adding that it has been unable to identify the rationale behind the DSMB's recommendation after reviewing blinded data.
The panel, consisting of pulmonary disease and biostatistics experts, will offer an independent recommendation and later collaborate with an expanded DSMB to reach a consensus on BEACON-IPF. The process is expected to conclude in 2 to 4 weeks.
Following the DSMB's recommendation, Pliant voluntarily paused enrollment and dosing in the BEACON-IPF trial while remaining blinded to preserve data integrity of the BEACON-IPF 2b and its potential as a registrational study, the company said.
Price: 3.48, Change: +0.76, Percent Change: +27.94
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。